The Israeli statutory corporate tax rate and real capital gains tax rate were 23% in 2025, 2024 and 2023. The combined U.S. federal and state tax rate was 28% in 2025, 2024 and 2023. The Canadian corporate tax rate was 27% in 2025, 2024 and 2023.

The assessments of the Company are deemed final through the 2019 tax year.

The Company has accumulated tax losses since its inception.

As of December 31, 2025, the Company’s net carryforward tax losses are estimated to be approximately $78,000, of which SNI’s losses amount to $1,300 and NeuroThera’s amount to $1,328.